{"id":"https://genegraph.clinicalgenome.org/r/b07301e7-5bcc-496e-b734-831e8c6c7055v1.0","type":"EvidenceStrengthAssertion","dc:description":"There is abundant evidence published associating the CYLD gene with Brooke-Spiegler syndrome, since the gene-disease relationship was first proposed by  Bignell et al. (2000). Multiple case level studies have been performed with BSS patients that have variants in the CYLD gene. CYLD protein is prominently expressed in the inner root sheath of hair follicles of human scalp as well as in eccrine glands.  Multiple articles reported no CYLD protein expression in the tumour tissue from BSS patients. Loss of CYLD inhibits apoptosis by activating NF-kappaB. Cyld also negatively regulate cell proliferation in keratinocytes and human Cylindroma tumors display hyperactive Wnt signaling. Cyld-/- mice are highly sensitive to skin tumor development under TPA or UV-B treatment. All of these types of evidence are consistent with a definitive relationship between the CYLD gene and Brooke-Spiegler syndrome.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/b07301e7-5bcc-496e-b734-831e8c6c7055","GCISnapshot":"https://genegraph.clinicalgenome.org/r/434ddb72-ee88-47af-9fa2-8dee9fa0a388","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/434ddb72-ee88-47af-9fa2-8dee9fa0a388_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10023","date":"2019-04-19T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/434ddb72-ee88-47af-9fa2-8dee9fa0a388_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10023","date":"2020-09-01T00:00:00Z","role":"Publisher"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/434ddb72-ee88-47af-9fa2-8dee9fa0a388_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/434ddb72-ee88-47af-9fa2-8dee9fa0a388_ad_null_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fc56c736-5f6a-4409-8f11-2d4dabdde891_proband_score_evidence_line","type":"EvidenceLine","dc:description":"A heterozygous 1-bp duplication (1392dupT) in exon 10 of the CYLD gene, predicted to result in a frameshift and premature termination.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1a2880e1-6e68-4714-9099-80eaadc1d642","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19807742","rdfs:label":"Patient 2","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":16,"detectionMethod":"","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypeFreeText":"spiradenomas","phenotypes":["obo:HP_0031024","obo:HP_0025367"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/fc56c736-5f6a-4409-8f11-2d4dabdde891_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19807742","allele":{"id":"https://genegraph.clinicalgenome.org/r/6188ca7e-6a82-45f3-af62-595cc3b8b95d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"CYLD, 1-BP DUP, 1392T","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/5261"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/83238841-c595-4d2a-8904-f1d3ccde87f9_proband_score_evidence_line","type":"EvidenceLine","dc:description":"A heterozygous 4-bp deletion (1950-1delGATA) in the acceptor splice site of exon 14 of the CYLD gene.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3bda196c-96dc-46fb-81f3-a761b65cdb33","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19807742","rdfs:label":"Patient 5","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":20,"detectionMethod":"","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":"obo:HP_0031024","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/83238841-c595-4d2a-8904-f1d3ccde87f9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19807742","allele":{"id":"https://genegraph.clinicalgenome.org/r/16ed467c-3388-45bd-b691-6ad5c5d9b65f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"CYLD, 4-BP DEL, 1950-1GATA","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/5262"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/c17879d1-5f1b-4bae-b622-3818eff0078b_proband_score_evidence_line","type":"EvidenceLine","dc:description":"A heterozygous 2272C-T transition in the CYLD gene, resulting in an arg758-to-ter (R758X) substitution.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4d819ce7-5622-42e5-8f03-3c183612cf53","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10835629","rdfs:label":"Family TT4","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"","firstTestingMethod":"PCR","phenotypes":"obo:HP_0031024","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/c17879d1-5f1b-4bae-b622-3818eff0078b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10835629","allele":{"id":"https://genegraph.clinicalgenome.org/r/b64451e4-9319-423f-9ae0-b3af6fbe5af2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_015247.2(CYLD):c.2272C>T (p.Arg758Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/5253"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/e64e8f0c-ac61-44e3-b362-7d3ee42dd6dc_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Increase points because 2 presumably unrelated families were reported with this variant.  It is a heterozygous G-to-A transition in the CYLD gene in the first position of a canonical splice donor site. Haplotype analysis indicated a common ancestor.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/81d94c1e-819d-4451-b40f-0fb1d0b74852","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10835629","rdfs:label":"Family TT2 and TT24","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"","firstTestingMethod":"PCR","phenotypes":"obo:HP_0031024","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/e64e8f0c-ac61-44e3-b362-7d3ee42dd6dc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10835629","allele":{"id":"https://genegraph.clinicalgenome.org/r/662bcafa-f7dd-423a-9b3d-f35f3e03b088","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"CYLD, NT2469, G-A, +1","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/5252"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/8ac698ef-0f41-4a53-8d2e-ab9693fdffdf_proband_score_evidence_line","type":"EvidenceLine","dc:description":"These were presumably independent mutations because the mutation was located on different haplotypes in the 2 families. The same R758X mutation was found as the 'second hit' (somatic mutation) in a familial cylindroma. Therefore, this mutation, which is at a CpG dinucleotide, appeared to have arisen on 3 separate occasions.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d60a1358-26de-4a56-a804-e88a6325f0a9","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10835629","rdfs:label":"Family TT23","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"","firstTestingMethod":"PCR","phenotypes":"obo:HP_0031024","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/8ac698ef-0f41-4a53-8d2e-ab9693fdffdf_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10835629","allele":{"id":"https://genegraph.clinicalgenome.org/r/b64451e4-9319-423f-9ae0-b3af6fbe5af2"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/de366f9e-9687-4086-bf2b-989589ee1fa3_proband_score_evidence_line","type":"EvidenceLine","dc:description":"A heterozygous 1-bp duplication (561dupT) in exon 5 of the CYLD gene, predicted to result in a frameshift and premature termination. The mutation occurred toward the N terminus of the protein in the first cytoskeleton-associated protein glycine-rich (CAP-GLY) domain, which is responsible for the interaction of CYLD with microtubules.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/81273de8-8f31-4e0c-9d08-66bff07f8e97","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19807742","rdfs:label":"Patient 1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":46,"detectionMethod":"","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":"obo:HP_0031024","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/de366f9e-9687-4086-bf2b-989589ee1fa3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19807742","allele":{"id":"https://genegraph.clinicalgenome.org/r/76662ca9-507f-464a-8371-af34ef6068cf","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"CYLD, 1-BP DUP, 561T","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/5260"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/4a0bc69d-e506-4e6e-9ebe-284b54cb271d_proband_score_evidence_line","type":"EvidenceLine","dc:description":"A heterozygous 2569C-T transition in the CYLD gene, resulting in an gln857-to-ter (Q857X) substitution.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c5f8f137-cb0c-4e26-8b99-488003cc4c57","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10835629","rdfs:label":"Family TT13","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"","firstTestingMethod":"PCR","phenotypes":"obo:HP_0031024","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/4a0bc69d-e506-4e6e-9ebe-284b54cb271d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10835629","allele":{"id":"https://genegraph.clinicalgenome.org/r/01d03611-b4d7-462a-b333-e67058be52b8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_015247.2(CYLD):c.2569C>T (p.Gln857Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/267255"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallAutosomalDominantNullVariantEvidenceCriteria","strengthScore":10},{"id":"https://genegraph.clinicalgenome.org/r/434ddb72-ee88-47af-9fa2-8dee9fa0a388_ad_other_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3adf06f8-95e1-4a10-b7c6-3c1157f696df_proband_score_evidence_line","type":"EvidenceLine","dc:description":"CYLD protein harboring D681G mutation had a significant reduced ability to inhibit TNF receptor-associated factor (TRAF)2- and TRAF6-mediated NF-kB activation, tumor necrosis factor-a (TNFa)-induced JNK signaling, and to deubiquitinate TRAF2. CYLD-D681G was coimmunoprecipitated by TRAF2, but was unable to cleave K63-linked polyubiquitin chains.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bfaa6277-c5fb-44fd-9f78-a1e58cf03b46","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17851586","rdfs:label":"Family F3 II-3","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"","firstTestingMethod":"PCR","phenotypes":"obo:HP_0025367","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/3adf06f8-95e1-4a10-b7c6-3c1157f696df_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17851586","allele":{"id":"https://genegraph.clinicalgenome.org/r/cb6d2de4-0c17-48a3-8ec4-4d3777185620","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000016.10:g.50787786A>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA395877395"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/074db973-7bc2-41f5-879a-3b911f6d63e3_proband_score_evidence_line","type":"EvidenceLine","dc:description":"A heterozygous 2240A-G transition in exon 16 of the CYLD gene, resulting in a glu474-to-gly (E747G) substitution. Although no direct functional evidence for this missense variant, it is a recurrent mutation which also reported in a USA family (Saggar et al., 2008).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b0d86954-171b-41a9-a6ee-d713392d9928","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14632188","rdfs:label":"Turkish family II-3","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"DNA from 13 affected and 3 unaffected family members were tested for mutations in the CYLD gene. The mutation E747G abolishes a restriction endonuclease site for the enzyme MnlI, which was used to confirm the mutation (Fig 2d).","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0031024","obo:HP_0025367"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/074db973-7bc2-41f5-879a-3b911f6d63e3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14632188","allele":{"id":"https://genegraph.clinicalgenome.org/r/0879f6b4-3a1d-479b-ba56-ee64f85ebc93","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_015247.2(CYLD):c.2240A>G (p.Glu747Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/5258"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallAutosomalDominantOtherVariantEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/434ddb72-ee88-47af-9fa2-8dee9fa0a388_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/79f4a41e-7038-4ed7-a1c5-54a4483c41c5_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10835629","rdfs:label":"Family TT23","family":{"id":"https://genegraph.clinicalgenome.org/r/79f4a41e-7038-4ed7-a1c5-54a4483c41c5","type":"Family","rdfs:label":"Family TT23","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/d60a1358-26de-4a56-a804-e88a6325f0a9"}},"phenotypeFreeText":"","phenotypePositiveAllelePositive":1,"phenotypes":"obo:HP_0031024","proband":{"id":"https://genegraph.clinicalgenome.org/r/d60a1358-26de-4a56-a804-e88a6325f0a9"}},{"id":"https://genegraph.clinicalgenome.org/r/1c14e1d6-dfe3-45f6-8df8-87b5ca73171f_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10835629","rdfs:label":"Family TT2 and TT24","family":{"id":"https://genegraph.clinicalgenome.org/r/1c14e1d6-dfe3-45f6-8df8-87b5ca73171f","type":"Family","rdfs:label":"Family TT2 and TT24","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/81d94c1e-819d-4451-b40f-0fb1d0b74852"}},"phenotypeFreeText":"","phenotypePositiveAllelePositive":1,"phenotypes":"obo:HP_0031024","proband":{"id":"https://genegraph.clinicalgenome.org/r/81d94c1e-819d-4451-b40f-0fb1d0b74852"}},{"id":"https://genegraph.clinicalgenome.org/r/a96be207-1b63-4b3f-8247-fd9d67856b5a_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10835629","rdfs:label":"Family TT4","family":{"id":"https://genegraph.clinicalgenome.org/r/a96be207-1b63-4b3f-8247-fd9d67856b5a","type":"Family","rdfs:label":"Family TT4","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/4d819ce7-5622-42e5-8f03-3c183612cf53"}},"phenotypeFreeText":"","phenotypePositiveAllelePositive":1,"phenotypes":"obo:HP_0031024","proband":{"id":"https://genegraph.clinicalgenome.org/r/4d819ce7-5622-42e5-8f03-3c183612cf53"}},{"id":"https://genegraph.clinicalgenome.org/r/0126db3b-51d4-4ca0-b859-3453452b5415_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17851586","rdfs:label":"Family F3","estimatedLodScore":0.9,"family":{"id":"https://genegraph.clinicalgenome.org/r/0126db3b-51d4-4ca0-b859-3453452b5415","type":"Family","rdfs:label":"Family F3","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/bfaa6277-c5fb-44fd-9f78-a1e58cf03b46"}},"meetsInclusionCriteria":false,"phenotypeFreeText":"","phenotypePositiveAllelePositive":4,"phenotypes":"obo:HP_0025367","proband":{"id":"https://genegraph.clinicalgenome.org/r/bfaa6277-c5fb-44fd-9f78-a1e58cf03b46"}},{"id":"https://genegraph.clinicalgenome.org/r/2180812c-2063-4fa7-9c8d-1fa7b5ae79cc_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10835629","rdfs:label":"Family TT13","family":{"id":"https://genegraph.clinicalgenome.org/r/2180812c-2063-4fa7-9c8d-1fa7b5ae79cc","type":"Family","rdfs:label":"Family TT13","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/c5f8f137-cb0c-4e26-8b99-488003cc4c57"}},"phenotypeFreeText":"","phenotypePositiveAllelePositive":1,"phenotypes":"obo:HP_0031024","proband":{"id":"https://genegraph.clinicalgenome.org/r/c5f8f137-cb0c-4e26-8b99-488003cc4c57"}},{"id":"https://genegraph.clinicalgenome.org/r/a884a0cf-0d4e-4d1d-ab40-1a11e67f36f7_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14632188","rdfs:label":"Turkish family","estimatedLodScore":3.61,"family":{"id":"https://genegraph.clinicalgenome.org/r/a884a0cf-0d4e-4d1d-ab40-1a11e67f36f7","type":"Family","rdfs:label":"Turkish family","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/b0d86954-171b-41a9-a6ee-d713392d9928"}},"meetsInclusionCriteria":true,"phenotypeFreeText":"","phenotypePositiveAllelePositive":13,"phenotypes":["obo:HP_0031024","obo:HP_0025367"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/b0d86954-171b-41a9-a6ee-d713392d9928"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/434ddb72-ee88-47af-9fa2-8dee9fa0a388_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/434ddb72-ee88-47af-9fa2-8dee9fa0a388_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/94b3903e-d835-4952-a7e4-2fbc62797005","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/58f52571-7c1f-43e3-a9e6-17f29a4a9aa1","type":"Finding","dc:description":"They induced skin tumors by treating Cyld\u0001-/-\u0001 mice and littermate controls with a single initiation dose of 7,12-dimethylbenz(a)anthracene (DMBA) followed by 12-O-tetradecanoylphorbol-13 acetate (TPA) twice per week. After a latency period of 7–11 weeks, all Cyld\u0001-/\u0001- mice developed tumors, whereas only 50% of Cyld+/+ mice developed papillomas after 11–16 weeks (Figure 1C and Figure 2A). Induced Cyld\u0001-/-\u0001 mice also developed 7-fold more and significantly larger papillomas than control littermates (Figures 2B and 2C).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16713561","rdfs:label":"Cyld-/- Mice Are Highly Sensitive to Skin Tumor Development","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/434ddb72-ee88-47af-9fa2-8dee9fa0a388_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0c152063-08e4-4340-b27f-c918cf8a05c9","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6805be75-5707-4f88-9b74-91773d469504","type":"FunctionalAlteration","dc:description":"All cylindroma tumors showed accumulation of nuclear b-catenin, a hallmark of hyperactive Wnt signaling (Figures 3A and 3B and Table S1). By in situ hybridization they observed enhanced levels of mRNA expression of the Wnt target gene, AXIN2, in distinct groups of cells in the majority of tumors (Figure 3C and Table S1).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20227366","rdfs:label":"Human Cylindroma Tumors Display Hyperactive Wnt Signaling"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/f4cdd590-b320-4fcc-8ee6-e11537f5d3c8","type":"EvidenceLine","dc:description":"Increase points because at least three independent assays were performed.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3a39c1c4-e90f-4ee5-b0db-055cd75b8940","type":"FunctionalAlteration","dc:description":"TPA or UV-B treatment significantly stimulated the proliferation of Cyld-\u0001/-\u0001, but not Cyld+/+, keratinocytes after 48 hr (Figure 3C) and induced a strong and progressive increase of cyclin D1 expression in Cyld\u0001-/-\u0001 keratinocytes, while cyclin D1 levels in Cyld+/+ keratinocytes decreased 12 hr after TPA treatment (Figure 3D). TPA or UV-B treatment increased cyclin D1 promoter activity significantly more in Cyld\u0001-/-\u0001 keratinocytes than in Cyld+/+ keratinocytes (Figure 3E and Figure S5). TNF-a decreased IkB-a levels more rapidly in Cyld\u0001-/-\u0001 than in Cyld+/+ keratinocytes (Figure 4A) and led to a significantly higher activation of the 3XkB luciferase reporter (3XkB) construct in primary Cyld\u0001/\u0001 keratinocytes compared to Cyld+/+ keratinocytes (Figure 4B).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16713561","rdfs:label":"Cyld negatively regulate cell proliferation in keratinocytes"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/434ddb72-ee88-47af-9fa2-8dee9fa0a388_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4ec60a12-c694-43f0-a23c-828554f04871","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/52b8f36c-5ad2-4b53-9095-e2eb338f2c51","type":"Finding","dc:description":"Inhibition of the familial cylindromatosis tumour suppressor gene (CYLD) enhances activation of the transcription factor NF-kappaB.  Inhibition of CYLD increases resistance to apoptosis, suggesting a mechanism through which loss of CYLD contributes to oncogenesis. Deregulated proliferation in the skin appendages in familial cylindromatosis results from a mild shift in the balance between proliferation and apoptosis in the favor of proliferation.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12917690","rdfs:label":"Loss of CYLD inhibits apoptosis by activating NF-kappaB.","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/946ddfad-3bec-4f6c-8f2e-5acd4b0b998a","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8e42536a-7557-4a3f-836d-45daaa0088f2","type":"Finding","dc:description":"As shown in Figure 2, normal scalp sections display prominent cytoplasmic immunoreactivity on the papilla, inner root sheath of hair follicles and eccrine coil with the antibody. In contrast, the CYLD protein was not detected by staining in the trichoepithelioma tumour tissue.  The CYLD protein is either down expressed or misexpressed in the tumour tissue of MFT.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17662085","rdfs:label":"no CYLD protein expression in the tumour tissue","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/4325e817-14c9-4bc1-a432-33b99083fb16","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ee077db8-30dc-4cd9-9c94-29545d4f6e47","type":"Finding","dc:description":"Cylindroma cryosections obtained during routine surgery from ‘‘turban tumors’’ of three female (60, 65, and 69 years old) patients with Brooke–Spiegler syndrome. Epithelial tumor islands in cylindroma show a reduced CYLD protein immunoreactivity or even lack it entirely; instead, expression of highly hair- specific keratins such as K6 and K17 could be observed.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16484982","rdfs:label":"Express human hair follicle keratins and CYLD in cylindroma","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/112e9910-56f3-453c-a3c8-7d52d3030e20","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bd84f3cd-a718-4462-8a83-02295a380960","type":"Finding","dc:description":"In immunostaining studies, CYLD protein is prominently expressed in the inner root sheath of hair follicles of normal human scalp.  Eccrine glands, especially the eccrine coil, also expressed CYLD proteins.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17662085","rdfs:label":"Immunohistochemical staining with anti-CYLD antibody","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":92,"specifiedBy":"GeneValidityCriteria6","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/ZOoPWZBzrXM","type":"GeneValidityProposition","disease":"obo:MONDO_0011512","gene":"hgnc:2584","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_434ddb72-ee88-47af-9fa2-8dee9fa0a388-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}